Latest Breaking News On - University nova de lisboa - Page 4 : comparemela.com
Conversational Bot to Promote COVID-19 Vaccination Among MS Patients
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.
Therini Plans to Move Antibody to Myelin-damaging Protein Into MS Trials
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.
Ever Changing Face of MS New CMSC, NeurologyLive Series for Doctors
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.
Gilenya is an oral treatment from Novartis that’s approved for relapsing forms of MS in people ages 10 and older. It works by retaining immune cells in lymph nodes (immune-related structures) and preventing them from reaching the brain and spinal cord, where they could cause damage to the protective myelin sheath surrounding nerve fibers.
By reducing the number of immune cells in circulation, Gilenya may reduce the immune system’s ability to fight off infectious pathogens. Yet, whether Gilenya treatment is associated with a greater risk of infections compared with other MS treatments remains controversial.
To shed light on this, researchers in China reviewed data from published clinical trials that assessed Gilenya, against a placebo or other disease-modifying therapies (DMTs), in MS patients.
4.6 (8)
Kesimpta (ofatumumab) has been approved in the U.K. as the first self-administered, at-home, B-cell-targeting therapy for people with relapsing forms of multiple sclerosis (MS) and active disease.
More specifically, the approval includes patients with either clinically isolated syndrome, relapsing-remitting MS (RRMS), or active secondary progressive MS (SPMS), who have been experiencing relapses or showing new lesions on MRI scans.
This approval by the Medicines and Healthcare Products Regulatory Agency (MHRA) follows similar decisions in the E.U., the U.S., Canada, Switzerland, Singapore, Australia, Japan, Argentina, the United Arab Emirates, Albania, and India.
The U.K.’s National Institute for Health Care and Excellence (NICE) and the Scottish Medicines Consortium now will decide whether to add Kesimpta to their respective National Health Service (NHS), which would allow patients to access treatments at low or no cost. NICE’s decision is